natgillin/translations-raw huggingface dataset:
Therefore, the present invention provides a method for diagnosing Alzheimer's disease (AD) wherein AB-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: contacting the sample with AB-aggregates or with particles having AB-aggregate like surfaces and allowing the AB-specific antibodies to bind to the AB-aggregates, and 
PATENTNI ZAHTJEVI Postupak za otkrivanje AB-specifičnih protutijela u biološkom uzorku, naznačen time, da obuhvaća sljedeće korake: - - stavljanje u doticaj uzorka s AB-agregatima ili s kuglicama koje imaju AB-agregate imobilizirane na svojoj površini, te dopuštanje AB-specifičnim protutijelima da se vežu na AB-agregate, i
Peptides can range in size from two amino acids to many amino acids. 
Peptidi mogu varirati u veličini od dvije do mnogo aminokiselina.
Amounts of sweetening agents may be typically comprised in the range of from 0.01 to 5% w/V, for example 0.05 to 1% w/V and for example from 0.05 to 0.5 % w/V and for example from 0.05 to 0.2%w/V. 
Otopina suklano bilo kojem patentnih zahtjevu od 1 do 3, pri čemu je propranolol ili njegove farmaceutski prihvatljive soli u količini od 0.01 do 5% tež/vol, primjerice 0.01 do 1% tež/vol.
There also many known high temperature sulfur sorbents that are part of the present invention. For example, the following compounds are known to react with sulfur at high temperature: zinc ferrite, zinc copper ferrite, zinc titanate, copper ferrite aluminate, copper aluminate, copper manganese oxide, nickel supported on alumina, zinc oxide, iron oxide, copper, copper oxide, limestone, and lime. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, ili modificirano zamjensko gorivo u skladu s bilo kojim patentnim zahtjevom 3 do 7, naznačeno time, da su dva ili više sorbensa odabrana iz skupine koju čine: trinatrij hidrogendikarbonat dihidrat (Trona), natrijev bikarbonat, natrijev karbonat, cinkov ferit, cink-bakar ferit, cinkov titanat, bakar-ferit aluminat, bakrov aluminat, bakar-oksid mangan, nikal na glini, cinkov oksid, željezni
A winch according to claim 2 wherein the spring mounting of the retainer guide is via the same spring mounting as for the upper and/or lower rope guide rings. 
Vitlo prema zahtjevu 2, naznačeno time, da je odskočna montaža povratne vodilice provedena putem iste odskočne montaže kao za gornje ifili donje prstenove za vođenje užeta.
The polymer hydrogel of claim 3 wherein the weight ratio of carboxymethylcellulose to hydroxyethylcellulose is greater than 1:1. 
Polimerni hidrogel u skladu s patentnim zahtjevom 3, naznačen time da je težinski omjer karboksimetilceluloze naspram hidroksietilceluloze u vodenoj otopini veći od 1:1.
A. Manual, Schlosser (Ed), John Wiley & Sons, Ltd (2002), ISBN 0471984167 followed by quenching with eletrophiles of the formula VIII. 
(2002.), ISBN 0471984167, a potom gašenjem s elektrofilima formule VIII.
An aqueous composition according to claims 1 to 6, wherein the aluminium-salt is aluminiumhydroxide (Al(OH)3) or aluminiumphosphate (AlPO4). 
Vodeni pripravak sukladno zahtjevima 1 do 6, pri čemu je aluminijumova sol aluminij hidroksid (AKOH)3) ili aluminij fosfat (AIPO4).
For single dose inhalers of the first type, single doses have been weighed by the manufacturer into small containers, which are mostly hard gelatine capsules. 
Kod ihnalatora za pojedinačnu dozu iz prve skupine, pojedinačne doze se tijekom proizvodnje odmjere u male spremnike koji su obično kapsula od tvrde želatine.
The composition of Claim 8, which comprises a therapeutically effective amount of a B2 adrenergic receptor agonist and a steroidal anti-inflammatory agent. 
Sastav prema zahtjevu 8, koji sadrži terapeutski učinkovitu količinu agonista beta2-adrenergičkih receptora i steroidnog protuupalnog agensa. rena .
The temperature of the release medium was 37° C. and the rotational speed of the stirrer 75 min−1. 
Temperatura medija za oslobađanje je iznosila 37C, a brzina okretanja miješalice 75 okretaja u minuti.
wherein a substituted aryl or heteroaryl group can be substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, carboxylate, alkylcarbonyl, cyano, amino, acylamino, sulfhydryl, alkylthio, arylthio, nitro, trifluoromethyl, and cyano; and wherein a substituted alkyl may be substituted by one or more substituents selected from the group consisting of alkenyl, alkoxy, alkoxycarbonyl, alkoxycarbonyloxy; alkynyl, alkylcarbonyl, alkylthio, alkythiocarbonyl, thiocarboxylate, arylthio, arylcarbonyl, arylcarbonyloxy, acylamino, carboxylate, cyano, halogen, haloalkyl, cycloalkoxy, acetamide, amine, hydroxyl, nitro, sulfhydryl, sulfonamido and trifluoromethyl; 
pri čemu supstituirana aril ili heteroaril skupina može biti supstituirana s jednim ili više supstituenata izabranih iz skupine koja se sastoji od halogena, hidroksila, alkoksija, alkilkarboniloksija, arilkarboniloksija, alkoksikarboniloksija, karboksilata, alkilkarbonila, cijano, amino, acilamino, sulfhidrila, alkiltio, ariltio, nitro, trifluorometila, i cijano; i gdje supstituirani alkil može biti supstituiran s jednim ili više supstituenata izabranih iz skupine koja se sastoji od alkenila, alkoksija, alkoksikarbonila, alkoksikarboniloksija; alkinila, alkilkarbonila, alkiltio, alkiltiokarbonila, tiokarboksilata, ariltio, arilkarbonila, arilkarboniloksija, acilamino, karboksilata, cijano, halogena, haloalkila, cikloalkoksija, acetamida, amina, hidroksila, nitro, sulfhidrila, sulfonamido i trifluorometila;
b.) reacting a compound of formula III with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base; or 
reagiranje spoja formule III [image] s organskom ili anorganskom bazom za tvorbu soli, eliminirajući acetonidnu skupinu i reagiranje s kalcij-kloridom u bazi; ili
The mixture was stirred for 30 min. after addition of TMSCI, cooled to 0 °C, and then quenched with a saturated aqueous solution of ammonium chloride. 
Smjesu se miješa 30 minuta nakon dodavanja TMSCI, ohladi do 0 "C, te ugasi zasićčenom vodenom otopinom amonijevog klorida.
in a dosage of about 0.5 mg to about 100 mg of the compound or pharmaceutically acceptable salt or solvate thereof, optionally administrable in divided doses of up to four times a day or in an extended release form. 
(li)u dozi od oko 0,5 mg do oko 100 mg spoja ili njegove farmaceutski prihvatljive soli ili solvata, koja se opcionalno primjenjuje u podijeljenim dozama do četiri puta dnevno ili u obliku s produženim oslobađanjem.
The angle between the first part and the second part of support 23, 24 and the angle between the third part and the fourth part of further support 28, 29 are preferably such that, following assembly of an empty car, the bottom part lies perpendicularly of uprights 21, 22 . 
Okvir (20, 200) prema zahtjevu 2, naznačen time da su udubljenje 1 prijelazni dio oblikovani tako da donja strana svakog uspravnog dijela (21, 22) leži u liniji s donjom stranom drugog dijela pripadajućeg nosača (23, 24).
The compounds are described as having various uses, including as reagents useful in characterizing glutathione S-transferase (GST) isoenzymes, in determining the GST complements of cells and tissues, as chromatographic affinity ligands, binding agents, and enzyme inhibitors; and therapeutically to: potentiate the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exert cytotoxicity in tumor cells, elevate the production of granulocyte-mactophage (GM) progenitors in bone marrow, stimulate the differentiation of bone marrow cells, mitigate the bone marrow-destructive effects of chemotherapeutic agents, and modulate hematopoiesis in bone marrow. 
Spojevi su opisani kao oni koji imaju različite upotrebe, uključujući i onu kao reagensi korisni u karakteriziranju glutation S-transferaze (GTS) izoenzima, u određivanju GST komplementarnih stanica 1 tkiva, kao ligandi kromatografskog afiniteta, agensi za vezivanje, i mhibitori enzima; i za terapiju: pojačavanje djelovanja citotoksika kemoterapijskih agensa u stanicama tumora, selektivno djelovanje citotoksiciteta u stanicama tumora, podizanje produkcije granulocit-makrofaga (GM) progenitora u koštanoj srži, stimuliranje diferencijacije koštane srži, ublažavanje destruktivnih efekata koštane srži zbog kemoterapijskih agenasa, i moduliranje hematopoiezisa u koštanoj srži.
The composition of claim 1, wherein the pharmaceutically acceptable salt is a sodium salt, potassium salt, calcium salt, magnesium salt, or quaternary ammonium salt. 
Sastav iz patentnog zahtjeva 1 ili 14, pri čemu je farmaceutski prihvatljiva sol natrijeva sol, kalijeva sol, kalcijeva sol, magnezijeva sol ili kvaternarna amonijeva sol.
The energy storing component as claimed in claim 1, wherein the at least one contact unit furthermore has an auxiliary voltage interface for transmitting an auxiliary voltage for supplying at least one of the contact unit or the gateway with electrical energy. 
Komponenta za pohranu energije prema bilo kojem od zahtjeva 1 do 3, naznačena time, da najmanje jedna kontaktna jedinica (12, 14) ima dodatno naponsko sučelje (38) za prijenos pomoćnog napona za napajanje kontaktne jedinice (12, 14) i/ili pristupnika (18) s električnom energijom.
or a salt thereof. The compound according to claim 1, wherein, in formula (1), R1 is a -CO-R8 group wherein R8 is an alkyl group, or a salt thereof. 
Spoj prema zahtjevu 1, naznačen time, da u formuli (1) R' je skupina -CO-(CH>),-COOH gdje n je cijeli broj od 1 do 4, ili njegova sol.
Embodiments of the present invention include those compounds wherein Ra and Rb are independently hydrogen or methyl. 
Spoj prema zahtjevu 1 naznačen time da R* i R* su nezavisno vodik ili metil.
The protecting group Pg may be removed from the compound of Formula XI using conventional techniques. 
Zaštitna skupina Pg može se ukoniti iz spoja prikazanog Formulom XI upotrebom konvencionalnih tehnika.
Experimental samples were incubated at 37 °C and the increase in absorbance at 234 nm was automatically recorded every 15 min for at least 12h. 
Pokusni uzorci su inkubirani pri 372C 1 porast apsorpcije pri 234 nm je automatski zabilježen svakih 15 min tijekom najmanje 12h.
The ActRII-Fc fusion protein for use of claim 1, wherein the amino acid sequence of the ActRII-Fc fusion protein consists of SEQ ID NO: 20. 
aminokiselinska sekvenca SEQ ID NO:20 ili aminokiselinska sekvenca koja je najmanje 95% identična sa SEQ ID NO: 20, i
The anhydrous crystalline form of claim 10 having an X-ray powder diffraction pattern as shown in Figure 1C. 
Bezvodni kristalinični oblik prema zahtjevu 10 koji ima uzorak rendgenske difrakcije praška kakav je prikazan na Slici 1C.
Process according to claim 3, wherein the said cheese spread comprises one or more flavourings, seasoning or inclusions at a level of 5% by weight, with respect to the total weight of the said cheese spread. 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time da navedeni obrađeni sir sadrži jednu ili više aroma, začinsko bilje i začine ili dodatke do udjela od 5 masenih % u odnosu na ukupnu masu navedenog obrađenog sira.
A nucleic acid molecule encoding a protein of any one of claims 1 or 2. 
Molekula nukleinske kiseline koja kodira autoaktivacijski protein proelastaze prema bilo kojem od patentnih zahtjeva od 1 do 4.
At the flow rate of 3 ml/min. there was a substantial decrease in r-hIL-18BP recovered in the elution fraction in comparison to that recovered at the flow rate of 1 ml/min. 
Pri brzini protoka od 3 ml/min došlo je do značajnog smanjenja r-hIL-18BP dobivenog u eluairanim frakcijama u usporedbi sa prinosom kod brzine protoka od 1 ml/min.
In some instances, the activation barrier (F*) is not sufficiently large to prevent premature transformation from the first phase to the second phase. 
U nekim primjerima aktivacijska barijera (F*) nije dovoljno visoka da spriječi preranu transformaciju iz prve faze u drugu fazu.
Use of the thiazole derivative according to any one of claims 1 to 7 or the pharmaceutically acceptable salt thereof, for the production of an agent for the treatment and/or prophylaxis of an anxiety disorder. 
Uporaba derivata tiazola koji je opisan u zahtjevu 1 ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju sredstva za liječenje i/ili profilaksu poremećaja anksioznosti.
The composition of claim 6, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier. 
Sastav prema bilo kojem od patentnih zahtjeva 6-8, naznačen time, da sastav jest farmaceutski sastav, a nosilac jest farmaceutski prihvatljivi nosilac.
(IIg): wherein the stereoisomeric configuration of carbon-1 and carbon-3 are of formula (II) respectively (S, R). 
Ry Ba pri čemu je stereoizomerna konfiguracija ugljenik-1 i ugljenik-3 respektivno (S, R) ili (5,5), i pri čemu Rž je cikloheksil i R*' je OR
The water was surcharged by 10% to avoid losses of evaporation. 
Voda je dodana u suvišku od 10% kako bi se izbjegao gubitak uslijed isparavanja.
Wind system (1) according to claim 2, characterised in that said trolley (11) is equipped with wheels (16, 17) to support said trolley (11) weight. 
Vjetreni sustav (1) prema zahtjevu 6, naznačen time da je spomenuta rastegnuta fleksibilna konstrukcija (12) opremljena jednom okomitom rešetkastom konstrukcijom (13).
The compound of claim 5, or a pharmaceutically acceptable salt or stereoisomer thereof, or the pharmaceutical composition of claim 7 for use in a method of treating, managing or preventing a disease or disorder, wherein the disease or disorder is cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, an infectious disease, hemoglobinopathy or a related disorder, or a TNFa related disorder. 
Spoj prema bilo kojem od zahtjeva 1-5, ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer naznačen time da je za uporabu u postupku za liječenje, upravljanje ili sprječavanje bolesti ili poremećaja, pri čemu bolest ili poremećaj je rak, poremećaj povezan s angiogenezom, bol, makularna degeneracija ili srodni sindrom, kožna bolest, plućni poremećaj, poremećaj povezan s azbestom, parazitska bolest, disfunkcionalni san ili srodni poremećaj, zarazna bolest, hemoglobinopatija ili srodni poremećaj, ili poremećaj povezan s TNFa.
Compounds are tested in full log dilution, from 0.1 nM to 10 µM in duplicate. 
Spojevi su ispitani u punom logaritamskom razrjeđenju, od 0,1 nM do 10 uM, u duplikatu.
According to a preferred aspect, such medicament is suitable as immunosuppressive agent. 
Prema poželjnom aspektu, takav lijek je pogodan kao imunosupresiv.
In another comparative test, freshly harvested pineapples were procured from an organic food store. 
U sljedećem usporednom testu, svježe ubrani ananasi su nabavljeni iz prodavaonice organske hrane.
The imaging material supply cartridge (24) of claim 1, wherein the memory (42) is mounted to an exterior of the body (34). 
Spremišna patrona za materijal za pisanje (24) u skladu s patentnim zahtjevom 1, naznačena time što se memorija (42) ugradi s vanjske strane tijela (34).
A compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 12 or a pharmaceutical composition of claim 13 for use as a medicament. 
Tvar ili farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 1 do 38 za uporabu kao lijek.
Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C1-6alkyl, halo-C1-6 alkyl, halogen and CF3; 
Q je izabran iz grupe koja se sastoji od fenil, piridil, tiazolil, tiofenil, pirimidil, svaka izborno supstituirana sa jednom ili dvije grupe nezavisno izabrane iz grupe koja se sastoji od C, .salkil, halo-C1.4 alkil, halogen i CF;;
It is another aspect of the present invention to provide a nucleic acid molecule encoding at least a binding molecule or functional variant thereof according to the invention. 
Molekula nukleinske kiseline za kodiranje molekule za vezanje, naznačena time, da je sukladna bilo kojem od patentnih zahtjeva 1-3.
A generally interesting aspect of the invention relates to a method of injecting a material into the human body comprising the use of the device of the invention. 
Najčešći aspekt ovog izuma, koji je od interesa, odnosi se na postupak injektiranja materijala u ljudsko tijelo, koji postupak obuhvaća upotrebu uređaja iz ovog izuma.
The method of any of the claims 11 to 14, wherein the GoP-structure associated with the determined array according to step d) is chosen to be the valid estimation of the GoP-pattern, field/frame status and open GoP/closed GoP status of the currently analysed series of frames. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 12 do 13, naznačen time što se strukturu GoP-a povezanu s određenom matricom u skladu s korakom d) tako bira ta bude važeće procjenjivanje uzorka GoP-a, status polja/kadra i otvoreni GoP/zatvoreni GoP status trenutno analiziranih nizova kadrova.
Cotransfection (CTF) Assays 
Ispitivanja na sutransfekciju (CTF)
A modified serpin according to claim 1 comprising an amino acid sequence having at least 70% sequence identity to residues 25-418 of SEQ ID NO: 12, wherein the P4 residue in the RCL of the modified serpin is A, the P2 residue is K, P1 residue is R and the P1′ residue is K. 
Modificirani serpin prema bilo kojem od zahtjeva 1 do 11, naznačen time, da on obuhvaća aminokiselinsku sekvencu koja ima najmanje 70% identiteta sekvence prema ostatcima 25-418 od SEQ ID NO: 12, pri čemu ostatak P4 u RCL-petlji od modificiranog serpina je A, ostatak P2 je K, ostatak P1 je R i ostatak P1' je Ki.
The method of claim 8, wherein said step (b) includes positioning the anti-refill fitment within the interior passage of the neck of the container such that an axial end of the fitment is flush with or recessed below an axially end surface of the neck of the container. The method of claim 8 also including, before said step (b), applying bonding material to the fitment. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 9 do 12. naznačen time što se nastavak koji onemogućuje ponovno punjenje sklapa u unutarnjem prolazu grla u navedenom koraku (c), tako da aksijalni kraj nastavka je poravnan s ili ubačen ispod površine aksijalnog kraja (29) grla spremnika.
Preferably, the transdermal dosage form is a transdermal patch. 
Preferira se da je transdermalni oblik doziranja u obliku transdermalnog flastera.
The present invention also relates to Form I for use in a method of treating cystic fibrosis as defined in claim 6 and its associated dependent claims. 
Oblik I iz zahtjeva 1 za upotrebu u liječenju cistične fibroze kod sisavaca koja sadrži davanje učinkovite količine navedenog Oblika I sisavcu.
The transdermal delivery device of claim 11, wherein the opioid antagonist is fentanyl or buprenorphine, pharmaceutically acceptable salts thereof, and mixtures thereof. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 12, naznačen time da je opioid agonist izabran iz skupine koja sadrži fentanil ili buprenorfin, njihove farmaceutski prihvatljive soli, ili njihove smjese.
The method according to claim 1, wherein the Enteroviral particles are of an Enterovirus selected from the group consisting of polioviruses, Coxsackie A viruses, Coxsackie B viruses, Echoviruses, Rhinoviruses and Enteroviruses 68, 69, 70, 71 and 73. 
Postupak prema bilo kojem od patentnih zahtjeva 1 - 7, naznačen time što su enterovirusne čestice iz roda Enterovirus odabrane iz grupe koja se sastoji od poliovirusa, Coxsackie A virusa, Coxsackie B virusa, echovirusa, rinovirusa i enterovirusa 68, 69, 70, 71173.
The method according to claim 1, wherein the operations on said apparatus, in particular the drawing or the storing of bags, are subordinate to a procedure for acknowledgment of the user through said interface. 
Postupak u skladu s patentnim zahtjevom 1, kod kojega su postupci na navedenom uređaju (1), naročito vađenje ili pohranjivanje vrećica, podložni postupku potvrđivanja od strane operatora preko navedenog međusklopa (8, 9).
The device of any of claims 1 to 13, wherein the flexible fiber optic tip member comprises a photoactive agent. The device of any of the preceding claims, suitable for use in the treatment of periodontal disease or wounds. 
Element fototerapijskog uređaja u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što vršni element fleksibilnog optičkog vlakna sadrži fotoaktivno sredstvo.
The composition for use according to any one of claims 1-7, wherein the lipid nanoparticle comprises a cleavable lipid. 
Sastav za upotrebu prema bilo kojem od patentnih zahtjeva 1-7, gdje lipidna nanočestica sadrži lipid podložan cijepanju.
A communications system according to claim 4, wherein the internet service provider is adapted to translate between a public dynamic routing protocol used by routers in the internet and the common private routing protocol. 
Komunikacijski sustav u skladu s patentnim zahtjevom 4, naznačen time što je davatelj internetskih usluga (102) prilagođen za prebacivanje između dinamičkog protokola za usmjeravanje kojeg upotrebljavaju usmjerivači unutar interneta (104) i zajedničkog privatnog protokola za usmjeravanje.
The compounds are therefore expected to act therapeutically in humans to: potentiate the cytotoxic effects of chemotherapeutic agents in tumor cells (because GST, especially GST P1-1, which is elevated in many tumor tissues, is implicated in the resistance of tumor cells to chemotherapeutic agents; so that a GST inhibitor will reduce the ability of the tumor cells to clear the chemotherapeutic agent), selectively exert cytotoxicity in tumor cells (again because of GST isoenzyme inhibition), elevate the production of GM progenitors in bone marrow, stimulate the differentiation of bone marrow, mitigate the myelosuppressive effects of chemotherapeutic agents, and modulate hematopoiesis in bone marrow. 
Prema tome očekuje se da spojevi djeluju terapeutski na čovjeka: pojačavaju citotoksični efekat kemoterapijskih agenasa u stanicama tumora (budući GST, posebno GST P1-1, koji poraste u mnogim tumorskim tkivima, umješan je u rezistenciju tumornih stanica na kemoterapijske agense; tako da će GST inhibitor reducirati mogućnost tumornih stanica da čiste kemoterapijski agens), selektivno pojačavanje citotoksiciteta u tumornim stanicama (opet zbog inhibicije GST izoenzima), raste produkcija GM progenitora u koštanoj srži, stimuliranje diferencijacije koštane srži, slabljenje mielosupresivnih efekata kemoterapijskih agenasa, i moduliranje hematopoiezisa u koštanoj srži.
a sensitizer material comprising said perovskite; and 
(b) senzibilizator koji sadržava navedeni perovskit i
The antisense oligonucleotide of claim 8, wherein the non-natural inter-nucleotide linkages are modified phosphates. 
Antisens oligonukleotid u skladu sa zahtjevom 8, naznačen time što neprirodne internukleotidne veze su modificirani fosfati.
The kit of claim 17, which further comprises a tool or tools for optimal insertion of said calcium carbonate containing biomaterial, and a series of calcium carbonate containing biomaterials of different sizes or shapes, or a combination of different sizes and shapes. 
Komplet za popravak hrskavice i kosti koji sadrži platformu sukladno zahtjevu 1; upute za korištenje spomenute platforme u tkivu popravak; i po izboru alat za optimalno umetanje navedene platforme, po izboru pri čemu spomenuti komplet obuhvaća niz platformi različitih veličina, oblika ili njihove kombinacije.